| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/ National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
ALTAIR [Japanese Treat-and- Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (ALTAIR)] |
288 patients (n=247 randomized to 2- or 4-week extension treatments after run-in phase) |
Regeneron/Bayer (NCT02305238) |
2017 |
Ohji M, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv Ther. 2020;37:1173-1187. https://link.springer.com/article/10.1007%2Fs12325-020-01236-x |
|